We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expiring Biologic Patents Could Bolster Pathway Legislation
Expiring Biologic Patents Could Bolster Pathway Legislation
December 8, 2006
With about $16 billion in biologic drug patents set to expire next year and the dramatic shift in the political climate on Capitol Hill, a clear pathway for FDA approval of follow-on biologics may be inching closer to becoming a reality, generic industry experts say.